TAK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 30, 2026Sponsor estimate | NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic Hypersomnia | TAKLead | Phase 2 | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2 | TAKLead | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic HypersomniaRecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2RecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 2026Sponsor estimate | NCT04009109Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMAlliance Foundation Trials, LLC. · Myeloma, Multiple | BMYCollaboratorTAKCollaboratorJNJCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Dec 2026Sponsor estimate | NCT05262023A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants...Denali Therapeutics Inc. · Frontotemporal Dementia | DNLILeadTAKCollaborator | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04009109Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMAlliance Foundation Trials, LLC. · Myeloma, MultipleActive, not recruitingBMYCollaboratorTAKCollaboratorJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05262023A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants...Denali Therapeutics Inc. · Frontotemporal DementiaActive, not recruitingDNLILeadTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT07011576A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)SCRI Development Innovations, LLC · Colon Cancer | TAKCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 2NCT07011576A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)SCRI Development Innovations, LLC · Colon CancerRecruitingTAKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 5, 2027Sponsor estimate | NCT07244263A Study of Zasocitinib in Adults With Hidradenitis SuppurativaTakeda · Hidradenitis Suppurativa | TAKLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Feb 17, 2027Sponsor estimate | NCT06233461A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active...Takeda · Crohn's Disease | TAKLead | Phase 2 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 5, 2027Sponsor estimatePhase 2NCT07244263A Study of Zasocitinib in Adults With Hidradenitis SuppurativaTakeda · Hidradenitis SuppurativaActive, not recruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2027Sponsor estimatePhase 2NCT06233461A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active...Takeda · Crohn's DiseaseRecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.